NASDAQ:CLNN Clene Q4 2024 Earnings Results & Report $4.04 +0.05 (+1.13%) As of 12:28 PM Eastern This is a fair market value price provided by Massive. Learn more. Clene missed analyst expectations on both earnings and revenue in its Q4 2024 results, released March 24, 2025. The company reported EPS of -$1.67 versus the -$1.21 consensus estimate, while revenue of $91 thousand fell short of the $130 thousand estimate by $39.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 24, 2025TimeBefore Market OpensConference Call9:00 AM ET Clene EPS ResultsActual EPS-$1.67Consensus EPS -$1.21Beat/MissMissed by -$0.46One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersClene Revenue ResultsActual Revenue$91 thousandExpected Revenue$130 thousandBeat/MissMissed by -$39.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Clene Q4 2024 Earnings FAQ Did Clene beat earnings estimates for Q4 2024? Clene (NASDAQ:CLNN) reported earnings of -$1.67 per share for Q4 2024, missing the consensus estimate of -$1.21. The report was announced on Monday, March 24, 2025. What was Clene's revenue for Q4 2024? Clene reported revenue of $91 thousand for Q4 2024, against a consensus estimate of $130 thousand. Clene Earnings HeadlinesClene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug ApplicationNovember 12 at 12:09 PM | businesswire.comResearch Analysts Set Expectations for Clene FY2026 EarningsNovember 8, 2026 | americanbankingnews.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 13 at 1:00 AM | Base Camp Trading (Ad)Clene (NASDAQ:CLNN) Stock Lifted to Hold by Wall Street ZenNovember 7, 2026 | americanbankingnews.comClene (CLNN) Expected to Announce Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comClene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 4, 2026 | marketscreener.comMSee More Clene Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Clene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clene and other key companies, straight to your email. Email Address About CleneClene (NASDAQ:CLNN) is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. The company’s lead product candidate, CNM-Au8, is an investigational oral suspension containing catalytically active gold nanocrystals designed to support cellular energy production and reduce oxidative stress, with the goal of protecting and improving the function of nerve cells. Clene has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), and has also investigated its potential applications in other neurodegenerative disorders. CNM-Au8 remains an investigational therapy and is not approved for general commercial use. Founded in 2013, Clene is headquartered in Salt Lake City, Utah, and conducts its research and clinical development activities primarily through U.S.-based programs, while working with research and clinical collaborators as appropriate. The company is led by Chief Executive Officer Robert Etherington and trades on the Nasdaq under the symbol CLNN.View Clene ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
